Identification of Novel Transcriptome Signature As a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33804433

Citations 14

Authors

Shuhua Zheng

Wensi Tao

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the most common and devastating type of primary brain tumor, with a median survival time of only 15 months. Having a clinically applicable genetic biomarker would lead to a paradigm shift in precise diagnosis, personalized therapeutic decisions, and prognostic prediction for GBM. Radiogenomic profiling connecting radiological imaging features with molecular alterations will offer a noninvasive method for genomic studies of GBM. To this end, we analyzed over 3800 glioma and GBM cases across four independent datasets. The Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases were employed for RNA-Seq analysis, whereas the Ivy Glioblastoma Atlas Project (Ivy-GAP) and The Cancer Imaging Archive (TCIA) provided clinicopathological data. The Clinical Proteomic Tumor Analysis Consortium Glioblastoma Multiforme (CPTAC-GBM) was used for proteomic analysis. We identified a simple three-gene transcriptome signature-, , and -that can connect GBM's overall prognosis with genes' expression and simultaneously correlate radiographical features of perfusion imaging with expression levels. More importantly, the rampant development of neovascularization in GBM offers a promising target for therapeutic intervention. However, treatment with bevacizumab failed to improve overall survival. We identified expression levels as a potential selection marker for patients who may benefit from early initiation of angiogenesis inhibitors.

Citing Articles

Analysis of ABCC3 in glioma progression: implications for prognosis, immunotherapy, and drug resistance.

Shen L, Shen H, Wang T, Chen G, Yu Z, Liu F Discov Oncol. 2025; 16(1):179.

PMID: 39948325 PMC: 11825434. DOI: 10.1007/s12672-025-01895-8.

Pepsinogen C Interacts with IQGAP1 to Inhibit the Metastasis of Gastric Cancer Cells by Suppressing Rho-GTPase Pathway.

Ding H, Liu Y, Lu X, Liu A, Xu Q, Yuan Y Cancers (Basel). 2024; 16(10).

PMID: 38791874 PMC: 11120368. DOI: 10.3390/cancers16101796.

The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.

Martin-Garcia D, Tellez T, Redondo M, Garcia-Aranda M Curr Med Chem. 2023; 31(39):6487-6509.

PMID: 37861026 DOI: 10.2174/0109298673261625230924114406.

A review of radiomics and genomics applications in cancers: the way towards precision medicine.

Li S, Zhou B Radiat Oncol. 2022; 17(1):217.

PMID: 36585716 PMC: 9801589. DOI: 10.1186/s13014-022-02192-2.

Exploring the multidimensional heterogeneities of glioblastoma multiforme based on sample-specific edge perturbation in gene interaction network.

Zheng J, Qiu Y, Wu Z, Wang X, Jiang X Front Immunol. 2022; 13:944030.

PMID: 36105808 PMC: 9464945. DOI: 10.3389/fimmu.2022.944030.

References

Burgenske D, Yang J, Decker P, Kollmeyer T, Kosel M, Mladek A . Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro Oncol. 2019; 21(11):1458-1469. PMC: 6827834. DOI: 10.1093/neuonc/noz129. View

Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P . The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013; 26(6):1045-57. PMC: 3824915. DOI: 10.1007/s10278-013-9622-7. View

Irandoust M, Aarts L, Roovers O, Gits J, Erkeland S, Touw I . Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO J. 2007; 26(7):1782-93. PMC: 1847666. DOI: 10.1038/sj.emboj.7601640. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Puchalski R, Shah N, Miller J, Dalley R, Nomura S, Yoon J . An anatomic transcriptional atlas of human glioblastoma. Science. 2018; 360(6389):660-663. PMC: 6414061. DOI: 10.1126/science.aaf2666. View

Gramatzki D, Roth P, Rushing E, Weller J, Andratschke N, Hofer S . Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018; 29(6):1431-1436. DOI: 10.1093/annonc/mdy106. View

Hou Z, Yang J, Wang H, Liu D, Zhang H . A Potential Prognostic Gene Signature for Predicting Survival for Glioblastoma Patients. Biomed Res Int. 2019; 2019:9506461. PMC: 6457303. DOI: 10.1155/2019/9506461. View

Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, von Deimling A . IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015; 5:16238. PMC: 4633672. DOI: 10.1038/srep16238. View

Fu Y, Zheng S, Zheng Y, Huang R, An N, Liang A . Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance. Int J Biochem Cell Biol. 2012; 44(5):770-5. DOI: 10.1016/j.biocel.2012.01.017. View

10.

Shih S, Robinson G, Perruzzi C, Calvo A, Desai K, Green J . Molecular profiling of angiogenesis markers. Am J Pathol. 2002; 161(1):35-41. PMC: 1850687. DOI: 10.1016/S0002-9440(10)64154-5. View

11.

Rui L, Yuan M, Frantz D, Shoelson S, White M . SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002; 277(44):42394-8. DOI: 10.1074/jbc.C200444200. View

12.

Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P . Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324(5924):261-5. PMC: 3251015. DOI: 10.1126/science.1170944. View

13.

Zhou H, Miki R, Eeva M, Fike F, Seligson D, Yang L . Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res. 2007; 13(8):2344-53. DOI: 10.1158/1078-0432.CCR-06-2303. View

14.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

15.

Pozzebon M, Varadaraj A, Mattoscio D, Jaffray E, Miccolo C, Galimberti V . BC-box protein domain-related mechanism for VHL protein degradation. Proc Natl Acad Sci U S A. 2013; 110(45):18168-73. PMC: 3831490. DOI: 10.1073/pnas.1311382110. View

16.

Wang L, Luan T, Zhou S, Lin J, Yang Y, Liu W . LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p. Cancer Med. 2019; 8(9):4389-4403. PMC: 6675706. DOI: 10.1002/cam4.2335. View

17.

Zhang L, He L, Lugano R, Roodakker K, Bergqvist M, Smits A . IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Neuro Oncol. 2018; 20(11):1505-1516. PMC: 6176806. DOI: 10.1093/neuonc/noy088. View

18.

Zhang J, Liu H, Tong H, Wang S, Yang Y, Liu G . Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. Contrast Media Mol Imaging. 2017; 2017:7064120. PMC: 5612612. DOI: 10.1155/2017/7064120. View

19.

Tanimoto K, Makino Y, Pereira T, Poellinger L . Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000; 19(16):4298-309. PMC: 302039. DOI: 10.1093/emboj/19.16.4298. View

20.

Sood V, Lata S, Ramachandran V, Banerjea A . Suppressor of Cytokine Signaling 3 (SOCS3) Degrades p65 and Regulate HIV-1 Replication. Front Microbiol. 2019; 10:114. PMC: 6365456. DOI: 10.3389/fmicb.2019.00114. View